154 related articles for article (PubMed ID: 24833447)
1. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
Yin VT; Wiraszka TA; Tetzlaff M; Curry JL; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2015; 31(4):e112-5. PubMed ID: 24833447
[TBL] [Abstract][Full Text] [Related]
2. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
Chu EY; Wanat KA; Miller CJ; Amaravadi RK; Fecher LA; Brose MS; McGettigan S; Giles LR; Schuchter LM; Seykora JT; Rosenbach M
J Am Acad Dermatol; 2012 Dec; 67(6):1265-72. PubMed ID: 22609219
[TBL] [Abstract][Full Text] [Related]
3. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib Active in Iodine-Refractory Thyroid Cancer.
Cancer Discov; 2016 Oct; 6(10):OF4. PubMed ID: 27554612
[TBL] [Abstract][Full Text] [Related]
7. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
[TBL] [Abstract][Full Text] [Related]
10. Eruptive squamous cell carcinomas after vemurafenib therapy.
Mays R; Curry J; Kim K; Tsai K; Arora A; Khan F; Ramirez-Fort M; Ciurea A
J Cutan Med Surg; 2013; 17(6):419-22. PubMed ID: 24138980
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.
Boussemart L; Routier E; Mateus C; Opletalova K; Sebille G; Kamsu-Kom N; Thomas M; Vagner S; Favre M; Tomasic G; Wechsler J; Lacroix L; Robert C
Ann Oncol; 2013 Jun; 24(6):1691-7. PubMed ID: 23406731
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib and cutaneous adverse events--report of five cases.
Silva Gde B; Mendes AP; de Macedo MP; Pinto CA; Gibbons IL; Duprat Neto JP
An Bras Dermatol; 2015; 90(3 Suppl 1):242-6. PubMed ID: 26312729
[TBL] [Abstract][Full Text] [Related]
13. Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.
Viros A; Hayward R; Martin M; Yashar S; Yu CC; Sanchez-Laorden B; Zambon A; Niculescu-Duvaz D; Springer C; Lo RS; Marais R
J Invest Dermatol; 2013 Jan; 133(1):274-6. PubMed ID: 22895366
[No Abstract] [Full Text] [Related]
14. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Oberholzer PA; Kee D; Dziunycz P; Sucker A; Kamsukom N; Jones R; Roden C; Chalk CJ; Ardlie K; Palescandolo E; Piris A; MacConaill LE; Robert C; Hofbauer GF; McArthur GA; Schadendorf D; Garraway LA
J Clin Oncol; 2012 Jan; 30(3):316-21. PubMed ID: 22067401
[TBL] [Abstract][Full Text] [Related]
15. Drug safety evaluation of vemurafenib in the treatment of melanoma.
Tsai KY; Nowroozi S; Kim KB
Expert Opin Drug Saf; 2013 Sep; 12(5):767-75. PubMed ID: 23800008
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
17. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF
Blank CU; Larkin J; Arance AM; Hauschild A; Queirolo P; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Garbe C; Chiarion Sileni V; Mandalà M; Gogas H; Espinosa E; Hospers GAP; Miller WH; Robson S; Makrutzki M; Antic V; Brown MP
Eur J Cancer; 2017 Jul; 79():176-184. PubMed ID: 28501764
[TBL] [Abstract][Full Text] [Related]
18. A model for cutaneous squamous cell carcinoma in vemurafenib therapy.
Kent R; Glorioso S; Nordberg ML
J La State Med Soc; 2012; 164(6):311-3. PubMed ID: 23431672
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
Russo I; Zorzetto L; Frigo AC; Chiarion Sileni V; Alaibac M
Eur J Dermatol; 2017 Oct; 27(5):482-486. PubMed ID: 29084636
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.
Huang V; Hepper D; Anadkat M; Cornelius L
Arch Dermatol; 2012 May; 148(5):628-33. PubMed ID: 22431713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
